Although clinical studies in this area are limited, emerging evidence suggests that the loss of ARID1A expression could serve as a biomarker for protein kinase B (AKT) pathway activation and might predict the effectiveness of AKT inhibitors in patients with GC [40,41,42,43]. This evidence concerns the gene ARID1A and gastric cancer.